114989-71-8

Upstream product

• 65882-96-4 1-hydroxyimino-1-(3-pyridyl)-2-propanone 
• 6302-03-0 1-(pyridin-3-yl)-2-propanone 
• 6419-36-9 3-pyridineacetic acid hydrochloride 
• 126436-24-6 4-acetylamino-2-methoxy-5-nitrobenzyl alcohol 
• 156601-83-1 4-acetylamino-2-methoxy-5-nitrobenzaldehyde 
• 4093-41-8 methyl 4-acetamido-2-methoxy-5-nitrobenzoate 
• 126436-30-4 2-(4-acetylamino-2-methoxy-5-nitrophenyl)-1-hydroxy-4-methyl-5-(3-pyridyl)imidazole 

Downstream Products

• 126436-42-8 2-(4-amino-2-methoxy-5-nitrophenyl)-5-methyl-4-(3-pyridyl)imidazole 
• 1025879-92-8 N-[2-Amino-5-methoxy-4-(5-methyl-4-pyridin-3-yl-1H-imidazol-2-yl)-phenyl]-acetamide 
• 126436-43-9 2-(4,5-diamino-2-methoxyphenyl)-5-methyl-4-(3-pyridyl)imidazole 

Relevant academic research and scientific papers

Studies on anti-platelet agents. II. Synthesis and platelet-inhibitory activity of 5-methyl-4-(3-pyridyl)-2-(substituted benzimidazol-5- yl)imidazoles

A series of 5-methyl-4-(3-pyridyl)-2-(substituted benzimidazol-5- yl)imidazole derivatives was synthesized and tested for anti-platelet and vasodilatory activities. Some compounds were found to have potent activities and low acute toxicity. In particular,

Studies on antiplatelet agents. I. Synthesis and platelet inhibitory activity of 5-alkyl-2-aryl-4-pyridylimidazoles

5-Alkyl-2-aryl-4-pyridylimidazoles were synthesized and tested in rat ex vivo platelet aggregation studies. Among these compounds, 2-(2-fluorophenyl)-5-methyl-4-(3-pyridyl)imidazole (25) was most potent, and showed 98% inhibition at a dose of 10 mg/kg (p.o.). 25 had inhibitory activity on cyclooxygenase, thromboxane A2 (TXA2) synthetase, and phosphodiesterase, and also showed inhibited KCl-induced contraction of rat aorta. All compounds have little acute toxicity and appear to be free of adverse effects on the stomach.